Data from Advances in Precision Cancer Care - Curated by EPG Health - Last updated 12 September 2019

We’re reporting live from ESMO 2018, Munich Germany. Join us as we take a look at some key data, abstracts and presentations. 

Advances in Precision Cancer Care is compiled by our Editorial Team including  Louise Todd, Tom Chown, Jacob Baker, Penny Staton, Georgina Mason, Allen Wellings,  Abhi Chakravorty and Adam Jeffery. 

Read the Day 1 article focusing on Lung Cancer

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Optimising anti-TNF treatment using biosimilars

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Load more

Blog posts by Advances in Precision Cancer Care

ESMO 2018 | Day 1 highlights

Today’s report come from the Proffered paper session - NSCLC, metastatic, focusing on presentations LBA50 and LBA51 discussing mechanisms of acquired resistance to osimertinib from the phase III trials FLAURA and AURA3, respectively.

Posted 1 year ago

ESMO 2018 | Day 2 highlights

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 

Posted 1 year ago

Related Content